Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Long-Acting Methylphenidate for Cancer-Related Fatigue: North Central Cancer Treatment Group NCCTG-N05C7 Trial
Authors:
- 10 August 2010
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (23) , 3673-3679
Abstract
Purpose: Fatigue is one of the most common symptoms experienced by patients with cancer. This trial was developed to evaluate the efficacy of long-acting methylphenidate for improving cancer-related fatigue and to assess its toxicities.Patients and Methods: Adults with cancer were randomly assigned in a double-blinded manner to receive methylphenidate (target dose, 54 mg/d) or placebo for 4 weeks. The Brief Fatigue Inventory was the primary outcome measure, while secondary outcome measures included a Symptom Experience Diary (SED), the Short Form-36 (SF-36) Vitality Subscale, a linear analog self-assessment, the Pittsburgh Sleep Quality Index, and the Subject Global Impression of Change.Results: In total, 148 patients were enrolled. Using an area under the serum concentration-time curve analysis, there was no evidence that methylphenidate, as compared with placebo, improved the primary end point of cancer-related fatigue in this patient population (P = .35). Comparisons of secondary end points, including clinically significant changes in quality-of-life variables and cancer-related fatigue change from baseline, were similarly negative. However, a subset analysis suggested that patients with more severe fatigue and/or with more advanced disease did have some fatigue improvement with methylphenidate (eg, in patients with stage III or IV disease, the mean improvement in usual fatigue was 19.7 with methylphenidate v 2.1 with placebo; P = .02). There was a significant difference in self-reported toxicities (SED), with increased levels of nervousness and appetite loss in the methylphenidate arm.Conclusion: This clinical trial was unable to support the primary prestudy hypothesis that the chosen long-acting methylphenidate product would decrease cancer-related fatigue.Keywords
This publication has 57 references indexed in Scilit:
- Placebo and nocebo effects in randomized double‐blind clinical trials of agents for the therapy for fatigue in patients with advanced cancerCancer, 2009
- Efficacy of Dexmethylphenidate for the Treatment of Fatigue After Cancer Chemotherapy: A Randomized Clinical TrialJournal of Pain and Symptom Management, 2009
- Cancer-related fatigue: Links with inflammation in cancer patients and survivorsBrain, Behavior, and Immunity, 2007
- Adult cancer survivors: How are they faring?Cancer, 2005
- Methods to Explain the Clinical Significance of Health Status MeasuresMayo Clinic Proceedings, 2002
- Interferon-Induced Fatigue in Patients With Melanoma: A Pilot Study of Exercise and MethylphenidateOncology Nursing Forum, 2002
- Methylphenidate for fatigue in advanced cancer: A prospective open-label pilot studyAmerican Journal of Hospice and Palliative Medicine®, 2001
- Methylphenidate: Its Pharmacology and UsesMayo Clinic Proceedings, 2000
- Affinities of methylphenidate derivatives for dopamine, norepinephrine and serotonin transportersLife Sciences, 1996
- The MOS 36-ltem Short-Form Health Survey (SF-36)Medical Care, 1992